Boston Scientific restructuring update
This article was originally published in The Gray Sheet
Executive Summary
Sale of Boston Scientific's cardiac surgery and vascular surgery units will be considered as part of the firm's ongoing effort to divest "non-strategic" assets to help cut costs and reduce debt, the company announces Aug. 16. The move comes on top of earlier plans to explore the sale of the firm's Namic fluid management business, announced July 24 (1"The Gray Sheet" July 30, 2007, p. 17), and the recent sale of its cochlear implant business (2"The Gray Sheet" Aug. 13, 2007, p. 11). Boston Scientific recently decided to retain its endosurgery and pain management businesses, however, following a review (3"The Gray Sheet" Aug. 6, 2007, In Brief). Boston Scientific acquired the cardiac surgery unit, which makes minimally invasive heart surgery devices and generates $189 million in annual sales, as part of its April 2006 acquisition of Guidant. The vascular surgery division, which makes aneurysm repair devices and generates sales of $86 million, was acquired with Meadox Medicals in 1995...